Product Images Dapagliflozin
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 17 images provide visual information about the product associated with Dapagliflozin NDC 63629-3253 by Bryant Ranch Prepack, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
Figure_4 - Figure 4
Figure_5 - Figure 5
Dapagliflozin Chemical Structure - dapagliflozin struct
Figure_1 - farxiga fig1
Figure_10a - figure 10a
Figure_10b - figure 10b
Figure_11 - figure 11 01
Not available*
Figure_8b - figure 8b
Not available.*
Figure-9b - figure 9b 01
Figure_2 - image 01
Not available*
Figure_3 - image 02
Not available.*
Figure_6 - image 03
This text provides information about a clinical study involving a drug called Dapagliflozin. The study compares the effectiveness of Dapagliflozin versus a placebo in a group of patients. The results show that patients taking Dapagliflozin had a lower incidence of an unspecified event compared to those taking the placebo. The Hazard Ratio (HR) is reported as 0.61 with a 95% confidence interval (CI) of 0.51 to 0.72. The p-value is noted as less than 0.0001, indicating a statistically significant difference between the two groups. The text also includes a chart showing the number of patients at risk over a span of 32 months from randomization.*
Figure_7a - image 04
This text contains information about patients who were given Dapagliflozin compared to placebo in a clinical trial. The number of patients with an event (%), the hazard ratio with a confidence interval, and the p-value are reported. Additionally, the number of patients at risk at different time points from randomization is provided.*
Figure-7b - image 05
Not available.*
Figure-8a - image 06
The text provides information about a comparison between Dapagliflozin and Placebo for treating patients, with data shown in terms of months from randomization and the number of patients at risk. The result suggests that Dapagliflozin may have a significant effect compared to Placebo, with a hazard ratio of 0.82 and a p-value of 0.0294.*
Figure-9a - image 07
Label - lbl636293253
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.